In Vitro Activity of Chloroquine Phosphate on the Antibacterial Potency of Ciprofloxacin Hydrochloride on the Clinical Isolates of Some Gram-Negative Microorganisms

The in vitro activity of chloroquine on the antibacterial effect of ciprofloxacin on some Gram-negative organisms was investigated using the in vitro standardized method of the National Committee for Clinical Laboratory Standard (NCCLS). The study showed that three of the four strains of Pseudomonas aeruginosa (PA1, PA2, and PA4) and the strain of Klebsiella pneumoniae (KP) isolates were sensitive to ciprofloxacin hydrochloride alone as well as in combination with chloroquine phosphate. However a strain of Pseudomonas aeruginosa (PA3) was sensitive to ciprofloxacin hydrochloride alone, but the sensitivity to ciprofloxacin hydrochloride was lost in the presence of chloroquine even at the lowest concentration of 1μg/ml. The two strains of Escherichia coli used were not sensitive to ciprofloxacin alone and in combination with chloroquine. There were no significant pharmacodynamic interaction between chloroquine and ciprofloxacin on the PA1, PA4 and KP strains used in vitro (p>0.05). On the other hand, a significant enhancement of in vitro antibacterial activities of ciprofloxacin by chloroquine on the strain PA2 at the various concentrations was observed (p<0.05). The inhibition, enhancement or lack of effect of chloroquine phosphate on the ciprofloxacin hydrochloride observed in this study depends on the type and strain of microorganism involved.

[1]  O. J. Kazzim,et al.  Additive effects of ciprofloxacin on the in-vitro activity of chloroquine against a clinical isolate of Plasmodium falciparum , 2006, Annals of tropical medicine and parasitology.

[2]  E. Randinitis,et al.  LACK OF A PHARMACOKINETIC INTERACTION BETWEEN AZITHROMYCIN AND CHLOROQUINE , 2006 .

[3]  D. Wirth,et al.  Relationship between Chloroquine Toxicity and Iron Acquisition in Saccharomyces cerevisiae , 2002, Antimicrobial Agents and Chemotherapy.

[4]  J. Reuning-Scherer,et al.  Comparison of Ciprofloxacin (7 Days) and Trimethoprim-Sulfamethoxazole (14 Days) for Acute Uncomplicated Pyelonephritis in Women , 2000 .

[5]  M. Nahata,et al.  Clinical Use of Fluoroquinolones in Children , 2000, The Annals of pharmacotherapy.

[6]  G. Mombelli,et al.  Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial. , 1999, Archives of internal medicine.

[7]  P. Vergne,et al.  Fluoroquinolone induced tendinopathy: report of 6 cases. , 1996, The Journal of rheumatology.

[8]  Paul Singleton,et al.  Bacteria in biology, biotechnology, and medicine , 1995 .

[9]  S. Foster,et al.  Economic prospects for a new antimalarial drug. , 1994, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[10]  E. Vinge,et al.  Neurologic Adverse Effects during Concomitant Treatment with Ciprofloxacin, Nsaids, and Chloroquine: Possible Drug Interaction , 1993, The Annals of pharmacotherapy.

[11]  A. J. Crowle,et al.  Inhibition of tubercle bacilli in cultured human macrophages by chloroquine used alone and in combination with streptomycin, isoniazid, pyrazinamide, and two metabolites of vitamin D3 , 1990, Antimicrobial Agents and Chemotherapy.

[12]  M. Lebel Ciprofloxacin: Chemistry, Mechanism of Action, Resistance, Antimicrobial Spectrum, Pharmacokinetics, Clinical Trials, and Adverse Reactions , 1988, Pharmacotherapy.

[13]  B. Eichelberger Textbook of Organic Medicinal and Pharmaceutical Chemistry , 1977 .

[14]  Ellen Jo Baron,et al.  Manual of clinical microbiology , 1975 .

[15]  A. Balows Bergey's Manual of Determinative Bacteriology. Eighth Edition , 1975 .

[16]  S. T. Cowan Bergey's Manual of Determinative Bacteriology , 1948, Nature.